In this study, impact surveys in six evaluation units of Malawi were used as a platform to explore associations between the prevalence of TF, ocular C. trachomatis infection and anti-Pgp3 antibodies one year after the third annual round of MDA.
This study aims to determine the effect of MDA for trachoma elimination on M. genitalium prevalence, strain type and azithromycin resistance.
To increase understanding of MDA impact, this study investigated the prevalence of active trachoma and ocular C. trachomatis prevalence, organism load, and circulating strains at baseline and one-year post-MDA in The Gambia and Senegal.
This study assess the evidence supporting the antibiotic arm of the SAFE strategy by assessing the effects of antibiotics on both active trachoma (primary objective), Chlamydia trachomatis infection of the conjunctiva, antibiotic resistance, and adverse effects (secondary objectives).
Community Eye Health Journal Vol. 32 No. 106 2019
This graph shows the total doses on Zithromax shipped and projected for trachoma elimination programs for 1999-2020.
This guide book explains how to successfully apply for, administer, and manage Zithromax® donations for trachoma elimination.
Conjunctival inflammation is the major clinical risk factor for progressive scarring trachoma, therefore, the reduction in inflammation associated with azithromycin treatment may be beneficial in limiting the development of potentially blinding disease sequelae.